Abstract:Introduction Gastric cancer (GC) is the fourth most common cancer and the third-leading cause of cancer-related deaths worldwide. Despite certain advances in chemotherapy regimens and targeted therapies, the 5 year survival of patients with advanced GC is disappointing. The positive results of the apatinib phase III trial have cast new light on treatment for patients with advanced gastric cancer (GC) refractory to two or more lines of prior systemic chemotherapies. However, a dose reduction or treatment interruption is required to prevent apatinib toxicity such as hand-foot skin reaction (HFSR), proteinuria, and hypertension. In addition, suitable biomarkers are not accessible for identifying the patients who are most likely to benefit from apatinib. Therefore, predictive biomarkers are urgently needed to reduce toxicity and identify patients that will benefit from apatinib treatment. Material and methods Clonogenic assay, cytotoxicity assay, apoptosis assay, qRT-PCR, western blot were conducted in GC cells to evaluate the effectiveness of apatinib in vitro. Confocal microscopy assay was peformed to examine apatinib-induced autophagic flux in GC cells. Transmission electron microscopy assay was conducted to show the formation of autophagic vesicles. Xenograft models in mice were conducted and six tumour tissues were sent for miRNA-seq and circRNA-seq. Sanger sequencing was applied to determine the full length of the amplification products. Results and discussions In this study, we found that apatinib inhibited the growth of GC cells and xenograft tumours. Apatinib promoted autophagy activation via upregulation of ATG7 expression, and autophagy inhibition enhanced apatinib-induced apoptosis. With miRNA-seq and circRNA-seq analyses of GC xenograft models, we demonstrated that circRNA004582 functioned as an endogenous sponge for miR-3657 to inhibit its activity and further upregulate ATG7 expression. Silencing of circRNA004582 inhibited apatinib-induced autophagy, which was rescued by miR-3657. Moreover, knockdown of circRNA004582 promoted apatinib-induced apoptosis in GC cells. These findings provided the first evidence that the circRNA004582-miR-3657-ATG7 axis mediates a regulatory pathway critical for the regulation of autophagy and apatinib sensitivity in GC cells and xenografts. Conclusion In conclusion, specific blockage of circRNA004582 may be a potential therapeutic target for autophagy inhibition in the context of apatinib treatment in human GC. Prospective clinical studies are warranted to examine these biomarkers.

Gastric cancer secreted miR-214-3p inhibits the anti-angiogenesis effect of apatinib by suppressing ferroptosis in vascular endothelial cells

Apatinib induced ferroptosis by lipid peroxidation in gastric cancer

Apatinib Enhances Chemosensitivity of FLT3-ITD Mutations acute Myeloid Leukemia Cells to Homoharringtonine Via VEGFR2 Pathway

CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer

Apatinib Suppresses Tumor Progression and Enhances Cisplatin Sensitivity in Esophageal Cancer Via the Akt/β-catenin Pathway.

MiR-124-3p mediates gastric cancer cell ferroptosis induced by an anti-cancer drug polyphyllin I

Docetaxel and 5-FU enhanced the inhibitory effects of apatinib and ramucirumab on growth and migration of gastric cancer

Silencing of Circracgap1 Sensitizes Gastric Cancer Cells to Apatinib Via Modulating Autophagy by Targeting Mir-3657 and ATG7

VEGFR-2 Inhibitor Apatinib Hinders Endothelial Cells Progression Triggered by Irradiated Gastric Cancer Cells-derived Exosomes.

PO-071 Silencing of Circrna004582 Sensitises Gastric Cancer Cells to APATINIB Via Modulating Autophagy by Targeting Mir-3657 and ATG7

Therapeutic Potential of Apatinib Against Colorectal Cancer by Inhibiting VEGFR2-Mediated Angiogenesis and -Catenin Signaling

Astragalus Polysaccharide Enhanced Antitumor Effects of Apatinib in Gastric Cancer AGS Cells by Inhibiting AKT Signalling Pathway.

Raltitrexed Enhances The Antitumor Effect Of Apatinib In Human Esophageal Squamous Carcinoma Cells Via Akt And Erk Pathways

Apatinib Inhibits Tumor Progression and Promotes Antitumor Efficacy of Cytotoxic Drugs in Esophageal Squamous Cell Carcinoma.

Polyphyllin I suppresses the gastric cancer growth by promoting cancer cell ferroptosis

Apatinib has anti-tumor effects and induces autophagy in lung cancer cells with high expression of VEGFR-2

Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer

Efficacy and safety of apatinib for the treatment of AFP-producing gastric cancer

Pyrotinib Treatment on HER2-positive Gastric Cancer Cells Promotes the Released Exosomes to Enhance Endothelial Cell Progression, Which Can Be Counteracted by Apatinib.

Actinidia chinensis Planch prevents proliferation and migration of gastric cancer associated with apoptosis, ferroptosis activation and mesenchymal phenotype suppression

Apatinib induces endoplasmic reticulum stress-mediated apoptosis and autophagy and potentiates cell sensitivity to paclitaxel via the IRE-1α–AKT–mTOR pathway in esophageal squamous cell carcinoma